Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Next Previous
X
Search
Trial Profile

A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel trevatide (Primary) ; Trastuzumab
  • Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; HER2 positive breast cancer; Meningeal carcinomatosis
  • Focus Therapeutic Use
  • Acronyms GRABM-B
  • Sponsors AngioChem

    • Most Recent Events

    • 22 Jan 2020 Results assessing efficacy of ANG1005 in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases, published in the Clinical Cancer Research.
    • 03 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2015 Results of a biomarker sub-study (n=10) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top